ArticleBlood2006
Persistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.
Article in Blood, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 139 citations in OpenAlex.
- Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis.Virology journal · 2023Pooled it
- Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Leukocyte telomere length in HIV-infected and HIV-exposed uninfected children: shorter telomeres with uncontrolled HIV viremia.PloS one · 2012Trial
- Quinobenzothiazine-AZT Hybrids Linked via 1,2,3-Triazole: Rational Design, Synthesis, and Biological Evaluation as Anticancer Agents.International journal of molecular sciences · 2026Article
- Current State of Therapeutics for HTLV-1.Viruses · 2024Review
- Treatment of Adult T-Cell Leukemia/Lymphoma: Established Paradigms and Emerging Directions.Current treatment options in oncology · 2023Review
- Small RNA Profiling in an HTLV-1-Infected Patient with Acute Adult T-Cell Leukemia-Lymphoma at Diagnosis and after Maintenance Therapy: A Case Study.International journal of molecular sciences · 2023Article
- Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.Nature reviews. Cancer · 2022Review
- Genetic Alterations in Adult T-Cell Leukemia/Lymphoma: Novel Discoveries with Clinical and Biological Significance.Cancers · 2022Review
- Cabotegravir, the Long-Acting Integrase Strand Transfer Inhibitor, Potently Inhibits Human T-Cell Lymphotropic Virus Type 1 TransmissionFrontiers in medicine · 2022Article
- Adult T-Cell Leukemia: a Comprehensive Overview on Current and Promising Treatment Modalities.Current oncology reports · 2021Review
- Transcription Independent Stimulation of Telomerase Enzymatic Activity by HTLV-I Tax Through Stimulation of IKK.Journal of cancer sciences · 2021Article
- Germinal epimutation of Fragile Histidine Triad (FHIT) gene is associated with progression to acute and chronic adult T-cell leukemia diseases.Molecular cancer · 2021Article
- Human T-cell Leukemia Virus Type 1 andPathogens (Basel, Switzerland) · 2020Review
- Azidothymidine "Clicked" into 1,2,3-Triazoles: First Report on Carbonic Anhydrase-Telomerase Dual-Hybrid Inhibitors.Journal of medicinal chemistry · 2020Article
- Molecular biology of human T cell leukemia virus.Seminars in diagnostic pathology · 2020Review
- New drugs are not enough‑drug repositioning in oncology: An update.International journal of oncology · 2020Review
- Diagnostic Approaches and Established Treatments for Adult T Cell Leukemia Lymphoma.Frontiers in microbiology · 2020Review
- STLV-1 as a model for studying HTLV-1 infection.Retrovirology · 2019Review
- Impact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL.Retrovirology · 2019Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
The antiviral thymidine analog azidothymidine (AZT) is used to treat several virus-associated human cancers. However, to date the mechanism of AZT action remains unclear and thus, reasons for treatment failure are unknown. Adult T-cell leukemia/lymphoma (ATL) is an aggressive malignancy of poor prognosis. Here, we report that enduring AZT treatment of T-cell leukemia virus I-infected cells, in vitro and in vivo in ATL patients, results in inhibition of telomerase activity, progressive telomere shortening, and increased p14(ARF) expression. In turn, this elicits stabilization and reactivation of the tumor suppressor p53-dependent transcription, increased expression of the cyclin-dependent kinase inhibitor p21(Waf1), and accumulation of p27(kip1), thereby inducing cellular senescence and tumor cell death. While ATL patients carrying a wild-type p53 enter remission following treatment with AZT, those with a mutated p53 did not respond, and patients' disease relapse was associated with the selection of a tumor clone carrying mutated inactive p53.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.